Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model
Gaspar J. Kitange(Hormel (United States)), Jann N. Sarkaria(Mayo Clinic in Arizona), Jan C. Buckner(McGill University), Brett L. Carlson(University of California, San Francisco), Paul A. Decker(University of California, San Francisco), C. David James(Mayo Clinic in Arizona), Karla V. Ballman(Mayo Clinic in Arizona), Ann C. Mladek(Mayo Clinic), Patrick T. Grogan(Moffitt Cancer Center), Mark A. Schroeder(MACOM (United States)), Caterina Giannini(Mayo Clinic), Wenting Wu(East China Normal University)
Cited by 97
Related Papers
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k
Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
|Journal of Clinical Oncology|2012|1.2k
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
|New England Journal of Medicine|2016|1k